ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Novo Nordisk will pay $1.8 billion to acquire Emisphere Technology, a US firm with technology for creating oral versions of biologic drugs that otherwise would have to be injected. Novo licenses the technology to formulate semaglutide, a diabetes drug it sells as Rybelsus. Emisphere’s technology is based on carriers, such as salcaprozate sodium, that enhance absorption of both small and large molecules.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter